By admin 
Abbott Laboratories has reached a comprehensive $385 million settlement to resolve a series of legal claims and federal investigations stemming from the 2022 shutdown of its infant formula production facility in Sturgis, Michigan. The agreement marks a significant turning point in a multi-year saga that exposed deep vulnerabilities in the United States’ food supply chain and left millions of parents struggling to find essential nutrition for their infants. The settlement addresses a complex web of litigation involving the U.S. Department of Justice (DOJ), the Attorneys General of several states, and private relators who filed claims under the False Claims Act. While the financial payout is substantial, Abbott has maintained that the agreement does not constitute an admission of fault or liability, framing the settlement as a strategic move to move past the regulatory and legal scrutiny that has dogged the company since the crisis began.
The roots of the settlement trace back to early 2022, when the Food and Drug Administration (FDA) launched an intensive investigation into the Sturgis plant, which was at the time the largest infant formula manufacturing site in the country. The investigation was prompted by reports of four infants who contracted Cronobacter sakazakii infections after consuming formula produced at the facility; tragically, two of those infants died. Although the link between the specific bacteria found in the plant and the strains that infected the infants remained a point of scientific contention, the FDA’s inspection of the Sturgis facility revealed systemic hygiene failures. Inspectors documented evidence of standing water, leaking roofs, and inadequate sanitation protocols, leading to a voluntary recall of several major powdered formula brands, including Similac, Alimentum, and EleCare.
The closure of the Sturgis facility in February 2022 acted as a catalyst for a nationwide catastrophe. Because Abbott Laboratories controlled approximately 40% of the domestic infant formula market, the sudden removal of its primary production hub created an immediate and localized vacuum. This vacuum was exacerbated by a highly concentrated market structure and the specific dynamics of the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). In many states, Abbott held exclusive contracts to provide formula to WIC recipients, meaning that low-income families were disproportionately affected when their approved brands vanished from store shelves. The shortage was further intensified by the lingering effects of COVID-19 pandemic disruptions, which had already strained global logistics and led to consumer stockpiling.
As the out-of-stock rates for infant formula soared above 40% across the United States, the Biden administration was forced to take unprecedented emergency measures. In May 2022, President Joe Biden invoked the Defense Production Act, requiring suppliers to prioritize the delivery of ingredients to formula manufacturers. Simultaneously, the administration launched "Operation Fly Formula," a massive logistical undertaking that utilized Department of Defense aircraft to transport millions of pounds of infant formula from overseas manufacturers in Europe and Australia. To facilitate this, the FDA temporarily eased strict labeling and import regulations, allowing foreign brands that met U.S. nutritional standards to enter the domestic market—a move that fundamentally altered the competitive landscape of the industry.
The legal fallout from the Sturgis crisis was equally intense. The Justice Department filed a complaint and a proposed consent decree in May 2022, alleging that Abbott had failed to comply with current Good Manufacturing Practices (cGMP). This legal pressure forced the company to enter into a court-ordered cleanup and oversight plan before it was permitted to restart production in June 2022. The $385 million settlement announced this week is the culmination of those federal pressures, alongside claims from state-level investigators who sought damages for the economic and public health toll the shortage took on their citizens. A portion of the settlement funds is expected to be allocated to the "relators"—whistleblowers who provided internal information regarding the plant’s operations—and to state governments to offset the costs associated with the emergency response.
Abbott’s defense throughout the investigation and subsequent litigation has remained consistent. In a statement following the settlement announcement, the company emphasized that rigorous testing by both internal teams and government regulators failed to find a direct genetic match between the Cronobacter sakazakii found in the Sturgis plant and the samples taken from the affected infants. Furthermore, Abbott highlighted that unopened containers of formula collected from the homes of the sickened infants tested negative for the bacteria. "No unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii," the company stated, suggesting that the infections may have occurred through environmental contamination in the homes rather than at the point of manufacture.
Despite these defenses, the FDA’s findings of environmental contamination within the plant were sufficient to trigger a massive regulatory overhaul. The crisis prompted a "top-to-bottom" review of the FDA’s food safety division, eventually leading to the creation of a unified Human Foods Program. External experts and internal auditors pointed to a breakdown in communication within the FDA, noting that a 34-page whistleblower report detailing safety concerns at the Sturgis plant had been sent to the agency months before the recall but was not acted upon promptly due to administrative errors and pandemic-related delays.
The economic impact of the $385 million settlement is significant, but it represents only a fraction of the total costs Abbott has incurred. The company reported hundreds of millions of dollars in lost sales and increased logistics costs during the months the Sturgis plant was offline. Moreover, the brand reputation of Similac, once the dominant name in infant nutrition, suffered a blow that allowed competitors like Reckitt (maker of Enfamil) and Perrigo to gain significant market share. The entry of international players like Kendamil and Bubs Australia, facilitated by the Biden administration’s emergency rules, has also introduced permanent new competition into what was once a relatively stagnant domestic market.
From a public health perspective, the Sturgis incident highlighted the unique risks associated with infant formula. Unlike most other food products, infant formula is often the "sole source of nutrition" for a vulnerable population with developing immune systems. Cronobacter sakazakii is a particularly resilient bacterium that can survive in dry environments like powdered formula for long periods. While rare, the infection can cause sepsis or meningitis, with a mortality rate that can exceed 40% in newborns. The settlement and the preceding consent decree have mandated that Abbott implement more frequent environmental testing and more stringent air-filtration and moisture-control systems at its facilities to prevent future outbreaks.
The political dimension of the crisis also remains relevant. While the Biden administration faced criticism for the initial speed of its response, it eventually leveraged the crisis to advocate for greater supply chain transparency and a reduction in market concentration. Conversely, the investigation into Abbott’s criminal liability, which had been initiated during the transition between the Trump and Biden administrations, was ultimately closed by the Justice Department without criminal charges. This closure paved the way for the civil settlement announced on Monday, allowing the government to recoup funds and impose oversight without the burden of a criminal trial.
Looking forward, the infant formula industry in the United States is under more scrutiny than ever before. The FDA has increased the frequency of its inspections and has become more aggressive in issuing warning letters for cGMP violations. For Abbott, the $385 million settlement serves as a final, expensive chapter in a crisis that redefined the company’s relationship with regulators and the American public. The Sturgis plant is now back in operation, producing formula under the watchful eye of an independent monitor, but the memory of empty store shelves and the fear of contaminated products continues to influence parental choices and federal policy.
As part of the broader resolution, the settlement also addresses the concerns of various state Attorneys General who argued that the shortage placed an undue burden on state-funded programs and created a public nuisance. By settling these claims collectively, Abbott avoids the prospect of dozens of individual state-level trials that could have dragged on for years. The resolution provides a measure of closure for the legal system, though for many parents who lived through the anxiety of 2022, the impact of the shortage remains a vivid reminder of the fragility of the systems that nourish the nation’s youngest citizens. The $385 million will be distributed according to a complex formula involving federal and state agencies, ensuring that the financial repercussions of the Sturgis failure are felt across the corporate balance sheet, even as the company moves to reclaim its position as a leader in pediatric nutrition.
